key: cord-0686475-yunrllst authors: Bai, Yan; Gao, Liwei; Wang, Xianfeng; Zhong, Lili; Li, Jingfeng; Ding, Shenggang; Zheng, Yuejie; Liu, Jun; Cui, Yuxia; Wang, Lina; Han, Mingfeng; Liu, Jun; Jiang, Xinping; Jiang, Min; Li, Junhua; Chen, Ning; Shang, Yunxiao; Zhou, Hourong; Xu, Yi; Lu, Gen; Chen, Xing; Xu, Jizhi; Fan, Qihong; Tang, Yu; Wu, Jiang; Li, Cen; Yang, Xiaoxiang; Chen, Chunxi; Yang, Yonghong; Wing‐Kin Wong, Gary; Shen, Adong; Wang, Tianyou; Jin, Runming; Xu, Baoping; Shen, Kunling title: Epidemiological characteristics and clinical manifestations of pediatric patients with COVID‐19 in China: A multicenter retrospective study date: 2021-08-12 journal: Pediatr Investig DOI: 10.1002/ped4.12282 sha: b060eb2d1ab5b79ed98a3d9609d6f68b72508b0b doc_id: 686475 cord_uid: yunrllst IMPORTANCE: The Coronavirus disease 2019 (COVID‐19) global pandemic poses a considerable challenge for pediatricians. OBJECTIVE: This study aimed to identify the epidemiological characteristics and clinical features of pediatric patients with COVID‐19 in China. METHODS: This multicenter retrospective study included pediatric patients from 46 hospitals in China, covering 12 provinces and two municipalities. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were analyzed. RESULTS: In total, 211 pediatric patients with COVID‐19 were included in this study. The median age was 7.0 years (range: 22 days to 18 years). Approximately 16.3% of the patients exhibited asymptomatic infections, 23.0% had upper respiratory tract infections, and 60.7% had pneumonia, including two with severe pneumonia and one with critical illness. Approximately 78.7% of the pediatric patients occurred in familial clusters. The most three common symptoms or signs at onset in children with COVID‐19 were fever (54.5%), cough (49.3%), and pharyngeal congestion (20.8%). Only 17.6% of the patients presented with decreased lymphocyte count, whereas 13.6% had increased lymphocyte count. Among the patients with pneumonia who exhibited abnormal chest computed tomography findings, 18.2% (23/127) of the patients had no other symptoms. Generally, the chest radiographs showed abnormalities that affected both lungs (49.6%); ground‐glass opacity (47.2%) was the most common manifestation. The cure and improvement rates were 86.7% (183/211) and 13.3% (28/211), respectively. Only one patient with an underlying condition received invasive mechanical ventilation; none of the patients died. INTERPRETATION: Similar to adults, children of all age groups are susceptible to COVID‐19. Fortunately, most pediatric patients have mild symptoms or remain asymptomatic, despite the high incidence of pneumonia. Decreased proportions of white blood cells and lymphocytes are less frequent in children than in adults. In December 2019, an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, was first reported in Wuhan, Hubei Province, China. [1] [2] [3] As of January 11, 2021, coronavirus disease 2019 (COVID- 19) had affected 90 669 019 individuals and resulted in 1 942 512 deaths. 4 People of all ages are susceptible to COVID-19. As a vulnerable group, children have received particular attention. Fortunately, compared with adult patients, the number of pediatric patients remains lower and their prognosis is better. A systematic review showed that the incidence of the disease in children comprised only 1%-6.4% of the total cases in multiple countries; moreover, the mortality rate was lower in children than in adults. 5 One study revealed that only 5.6% (112/2143) of infected children developed severe disease (i.e., hypoxia), whereas only 0.6% developed multi-organ failure or acute respiratory distress syndrome. 6 The mortality rate is less than 1% in children. Nevertheless, because of the global COVID-19 pandemic, there has been a growing number of reported pediatric patients, which poses a considerable challenge for pediatricians. Thus, to gain more knowledge regarding COVID-19 in pediatric patients, we analyzed the epidemiological and clinical features of 211 COVID-19 pediatric patients from 46 hospitals in China. The study design was in accordance with the Helsinki Declaration and was approved by the Beijing Children's Hospital Ethics Committee (Approval number 2020-K- 20) . Because this was a retrospective study and data were analyzed anonymously, informed consent was waived. This multicenter study included pediatric inpatients (≤ 18 years old) with confirmed COVID-19 diagnosis, from 46 hospitals in China-12 provinces [Hubei except Wuhan (51), Guangdong (46), Hunan (37), Anhui (25) , Guizhou (18) , Shandong (9) , Henan (5), Guangxi (4), Hainan (3), Hebei (3), Heilongjiang (2), Jilin (1)] and two provincelevel municipalities [Beijing (4) and Tianjin (3)]-between January 16, 2020 and February 25, 2020. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardized data collection form. Patients who had epidemiological history and any two clinical manifestations matching the diagnostic criteria were suspected to have SARS-CoV-2 infection: 1) the patients had symptoms of fever, fatigue, and/or dry cough; 2) chest imaging showed bilateral multiple groundglass opacity and/or obvious infiltrating shadows in the lung periphery); 3) during the early phase of the disease, white blood cell counts were normal or decreased, or the lymphocyte count was decreased. Confirmed cases of COVID-19 were defined as "suspected patients who had tested positive for SARS-CoV-2 by reverse transcriptionpolymerase chain reaction (RT-PCR) assay on nasal and pharyngeal swab specimens". Clinical classifications were defined in accordance with previous reports. 7, 8 1. Asymptomatic infection (silent infection) was recorded for children who tested positive for SARS-CoV-2 infection, but did not exhibit corresponding clinical symptoms or abnormal chest imaging findings. 2. Acute upper respiratory tract infection was recorded for children who exhibited symptoms such as fever, cough, pharyngeal pain, nasal congestion, fatigue, headache, myalgia, or discomfort; however, they did not demonstrate sepsis or signs of pneumonia according to chest imaging analysis. 3. Pneumonia was recorded for children who had respiratory symptoms such as fever, cough, tachypnea, and chest imaging alterations. These patients were subdivided into mild, severe, and critically ill patients, as follows. Mild pneumonia referred to patients that did or did not involve fever, respiratory symptoms (e.g., cough), and chest imaging findings indicative of pneumonia; however, the manifestations did not meet the criteria for severe pneumonia. Severe pneumonia referred to patients that met any of the following criteria: 1) increased respiratory rate: ≥ 70 breaths/min (for children under 1 year of age) or ≥ 50 breaths/min (for children above 1 year of age), following the exclusion of potential interference caused by fever or crying; 2) oxygen saturation < 92%; 3) hypoxia: assisted breathing (e.g., moans, nasal flaring, and/or retractions of supraclavicular, substernal, and intercostal spaces), cyanosis, and/or intermittent apnea; 4) disturbance of consciousness: somnolence, coma, or convulsion; 5) food refusal or feeding difficulty, with signs of dehydration. Critically ill patients referred to patients who met any of the following criteria and required admission to the intensive care unit: 1) respiratory failure requiring mechanical ventilation; 2) shock; and 3) multi-organ failure. The incubation period was defined as the interval between the putative earliest date of contact with the infectious source (i.e., person with suspected or confirmed infection) and the earliest date of symptom onset (e.g., cough, fever, fatigue, or myalgia). Lymphocytopenia was defined in accordance with the standards in the Zhu Futang Textbook of Pediatrics [reference ranges: (2.9-8.8) × 10 9 /L (< 3 months), (3.6-8.8) × 10 9 /L (4-8 months), (2.1-8.2) × 10 9 /L (9 months to 2 years), and (2.0-2.7) × 10 9 /L (3-18 years)]. 9 All analyses were conducted with SPSS Statistics, version 22.0. The Wilcoxon rank-sum test was used to compare continuous variables, while Fisher's exact test was used to compare categorical variables. Results were considered statistically significant when P < 0.05. including preterm birth (n = 4), recurrent respiratory tract infection (n = 6), congenital heart disease (n = 3), asthma (n = 2), suspected primary immunodeficiency (n = 2), epilepsy (n = 1), and tumor (n = 1). Eleven of the patients with underlying conditions were diagnosed with mild pneumonia, while one was critically ill. Approximately 82.5% (174/211) of the patients had a history of exposure or contact with confirmed COVID-19 patients, 33.2% (70/211) had a history of travel to or residence in Wuhan, and two had a history of exposure to the South China Seafood Market. Moreover, 78.7% (166/211) of the patients occurred in familial clusters of infection ( Table 1 ). The median incubation time was 10 days (range: 1-34 days). The median interval from symptom onset to disease confirmation was 1 day (range: 0-14 days). The most common sign or symptom at the onset of disease was fever (54.5%, 115/211), defined as a body temperature > 37.3°C. Approximately 43.1% of the patients had low-grade fever (37.3-38.0°C); a few patients (17.2%) exhibited high-degree fever (> 39.0°C). The median duration of fever was 2.5 days (range: 0.5-20 days), while two patients exhibited persistent fever for 20 days. The second most common symptom was cough (49.3%, 104/211); 57 patients exhibited dry cough and 47 patients Table 3) . The most common feature on chest radiography was ground-glass opacity (47.2%), followed by patchy shadows (40.2%), and a combination of ground-glass opacity with patchy shadows (12.6%). There were no patients with pleural Data are presented as n/N (%). † Not all of the 199 patients performed the following laboratory tests. ‡ The 199 patients included two cases who cannot be divided into any of the three groups (asymptomatic infection group, upper respiratory tract infection group or pneumonia group) because they did not undergo chest imaging exam. Reference ranges: white blood cells, (4-10)×10 9 /L; lymphocytes, (2.9-8.8) × 10 9 effusion in this study. Radiographic images from two patients with severe pneumonia and one case with critical illness showed bilateral lung involvement. In total, 196 patients received anti-viral treatment, including 124 patients treated with interferon alpha; the remaining patients were treated with either oseltamivir, Arbidol, ribavirin, or lopinavir/ritonavir. Intravenous immunoglobulins and systemic corticosteroids were used in the treatment of two patients with severe pneumonia and one case with critical illness for 3-4 days. Moreover, the patient with critical illness received mechanical ventilation. This patient had suspected immunodeficiency and a history of open-heart surgery due to congenital heart disease. Additionally, some patients were treated with traditional Chinese medicine. All 211 patients had improved conditions and were cured eventually. None of the included patients died. At the beginning of the COVID-19 outbreak, most confirmed patients were adults. Over time, an increasing number of pediatric patients were reported. 6,10-12 Ludvigsson's 13 systematic review of 45 relevant scientific papers and letters showed that, compared with adults, pediatric patients comprised fewer than 7% of the diagnosed patients of COVID-19; moreover, pediatric patients often exhibited milder disease and rarely died. These results are similar to the findings of our study, in that all pediatric patients had good prognosis. Compared with adults, children with COVID-19 demonstrate a milder clinical course. Previous studies reported that children with COVID-19 were hospitalized less frequently than adults with COVID-19; furthermore, fewer children with COVID-19 experienced fever, cough, or shortness of breath. 11, 14 Khamis et al 15 No pediatric deaths were reportedly caused by SARS, while only two pediatric deaths were reportedly caused by MERS. [16] [17] [18] The reasons for lower numbers of infections and severity in children are unclear and might be related to the intrinsic features of children. First, children may be less physiologically susceptible to SARS-CoV-2 because they exhibit lower expression levels of angiotensinconverting enzyme 2 (ACE2) receptors in lung tissue. 19 Second, the immaturity of the pediatric immune system might prevent severe immunopathological injuries, which are important in the immunopathology of COVID-19 infection in adults. 20 Children of all ages are susceptible to COVID-19, and most studied patients were previously healthy. Our study found that the median age (7.0 years) of children with COVID-19 was similar to the age range reported in previous studies (7-11 years) . 10, 21 A study performed in the United States revealed that 10.6% of infants developed severe COVID-19, compared with 5.8% of older children. 11 This finding indicated that infants infected with SARS-CoV-2 develop more severe disease, need more attention, and should be further protected. In our study, 83.3% of the pediatric patients had a history of exposure or contact with confirmed COVID-19 patients, and 78.7% had been infected during outbreaks in family clusters. These findings were similar to the results in previous studies. 10, 11 In the United States, the incidence related to outbreaks in family clusters was 91%. 6 Thus, for the diagnosis of COVID-19 in pediatric patients, the epidemiological history is a prominent factor. The three most common symptoms or signs at onset of COVID-19 found in this study were fever (54.5%), cough (49.3%), and pharyngeal congestion (20.8%), consistent with the findings in previous studies. 10, 11 In contrast, the most common symptoms in adults were fever (98%), cough (76%), and fatigue (44%). 19 Contrary to adults, 45.5% of pediatric patients were afebrile; most febrile children had low to moderate fever. In addition, the proportion of dyspnea was much lower in pediatric patients than in adult patients. Only one child with respiratory failure required mechanical ventilation support in this study. Furthermore, only 14.1% of the patients had decreased WBC count, while 17.6% had decreased lymphocyte count, which is similar to the results in a previous study. 13 Presumably, SARS-CoV-2 directly destroys T lymphocytes by binding their ACE2 receptors, thus decreasing their counts. Because the expression of ACE2 receptors on T lymphocytes is considerably lower in children than in adults, the decreases in WBC and lymphocyte counts mainly occur in adults. 22 The clinical symptoms and signs of COVID-19 in pediatric patients are similar to the symptoms and signs of other respiratory virus infections in pediatric patients. Fever and cough are the most common symptoms, both in SARS-CoV-2 pneumonia and pneumonias caused by other respiratory pathogens. Compared with influenza A pneumonia in children under 5 years of age, comparatively lower proportions of fever, cough, sputum production, shortness of breath, and abnormal pulmonary auscultation were observed in pediatric patients with COVID-19. 23 Lymphopenia was also found in patients with severe influenza and other respiratory viral infections. Nevertheless, the clinical, epidemiological, and radiological features of COVID-19 might help to distinguish it from other respiratory viral infections. 24 In addition, since April 2020, clinicians in the United Kingdom, Italy, and the United States have reported a rare and severe inflammatory syndrome in children with COVID-19 [i.e., multisystem inflammatory syndrome in children (MIS-C)]. Affected children exhibit multiple system dysfunction, including manifestations similar to typical Kawasaki disease; these range from inflammation to myocardial injury, shock, coronary artery aneurysms, and mucocutaneous manifestations. However, these manifestations are rarely concomitant with respiratory symptoms 25 and imply a diffuse inflammatory process. 26 Our study did not identify any case with MIS-C, and further clinical observations are needed to detect such patients. This study had a few limitations. First, it was a retrospective multi-center study; included patients were treated at one of 46 hospitals. Therefore, some information was incomplete. Second, we could not evaluate the efficacies of the drugs that were used to treat children with COVID-19. A randomized controlled trial is needed to determine the optimal treatment. In conclusion, children of all ages are susceptible to COVID-19, but the greatest proportion of patients occurred in children aged 6-12 years. Most pediatric patients with COVID-19 had a milder disease course and better prognosis, compared with adults. The proportions of leukopenia and lymphopenia were lower in affected children than in affected adults. Children who were exposed to family clusters of infection or had contact with a confirmed case should be tested to ensure a timely diagnosis. Yuehua Zhang (Affiliated Haikou Hospital of Xiangya Medical College We also thank all patients and their legal guardians for their active participation and cooperation in this study and Dr A novel coronavirus from patients with pneumonia in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding COVID-19 Coronavirus Pandemic COVID-19 in children: Present and future perspective, an interim review Epidemiology of COVID-19 among children in China Diagnosis, treatment and prevention of 2019 novel coronavirus infection in children: experts' consensus statement National Health Commission of the People's Republic of China. Diagnosis and treatment protocol for COVID-19 Beijing: People's Medical Publishing House Co SARS-CoV-2 infection in children Clinical characteristics of children with coronavirus disease 2019 in Hubei, China Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults Epidemiological and clinical characteristics of 35 children with COVID-19 in Beijing Clinical and laboratory findings of COVID-19: A systematic review and meta-analysis Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China Clinical analysis of pediatric SARS cases in Beijing Middle East respiratory syndrome coronavirus in children Neutrophilto-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage SARS-CoV-2 and viral sepsis: observations and hypotheses COVID-19 in children: Epidemiology, presentation, diagnosis and management Single-Cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2 Comparison of hospitalized patients with pneumonia caused by COVID-19 and influenza A in children under 5 years Radiographic and CT features of viral pneumonia Clinical characteristics of 58 Children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 COVID-19 in children: A review and parallels to other hyperinflammatory syndromes We would like to acknowledge the contributions of researchers from all participating hospitals: Shi Chen (Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Hainan, China), Litao Chang The authors have no conflict of interest to disclose.